Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Pediatric Loophole To Be Closed By US FDA

Executive Summary

Commissioner Gottlieb hopes accomplish through guidance a policy change that advocates failed to get included in user fee legislation passed earlier this year.


Related Content

Orphan Designations For Pediatric Subgroups Of Common Diseases To End
Orphan Drug Pricing Doesn't Drive Healthcare Costs, NORD Argues
Pediatric Cancer Study Requirements Added To FDA User Fee Bill
FDA's Orphan Designation Backlog Plan Focuses On Efficiency, Not Staff
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
Speaking Up For Orphan Drugs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts